• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Stryker dismisses Boston Scientific buyout rumors, sees shares rebound

Stryker dismisses Boston Scientific buyout rumors, sees shares rebound

June 13, 2018 By Fink Densford

Stryker, Boston Scientific

Stryker (NYSE:SYK) today put the rumors that it was interested in a takeover of  Boston Scientific (NYSE:BSX) to rest and has seen shares rise in response.

Rumors emerged of a possible takeover bid from the Kalamazoo, Mich.-based company emerged on Monday in a Wall Street Journal report, after which both companies officially responded with statements of “no comment.”

Today, Stryker stated that it “is not in discussions with Boston Scientific regarding a potential acquisition,” according to an SEC filing. The company said that it normally doesn’t comment on such matters, but that it issued the statement in response to market speculation.

Shares in Stryker saw a significant drop after the announcement, having lost 9.1% since Monday, down $16.43 to $162.54. Stryker shares are now rebounding in pre-market trading today, up 7% at $174, as of 8:57 a.m. EDT.

Shares in Boston Scientific have fallen 6.6% in pre-market trading, at $31.60 as of 9:12 a.m. EDT.

Analysts, though surprised by the deal, said that a possible merger between the two companies could have formed a “higher growth Medtronic.”

Filed Under: Business/Financial News, Mergers & Acquisitions, Wall Street Beat Tagged With: Boston Scientific, Stryker

More recent news

  • Mass. Life Sciences Center offers grants for lowering medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy